August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. [Read more…]
Sponsored Content: Press releases may be published as paid or sponsored content. The issuers of these press releases are solely responsible for their content. BioInformant is not responsible for the accuracy or claims made in these announcements and does not endorse the views expressed by their issuers.
CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy
Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]
denovoMATRIX Launches Cell Therapy Grade Consumables
DRESDEN, Germany, September. 19, 2022 /BioInformant/ — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, announced the launch of its animal component-free product lines at cell therapy grade (CTG). The new product lines will include documentation and traceability information for compliance with industry regulatory standards, designed for the stem cell therapy manufacturing market.
Steakholder Foods™ announces Omakase Beef Morsels, a first-of-its-kind, highly marbled 3D-printed 100% cultured beef cut
The new product is a result of the company’s recently filed patent for 3D-bioprinting technology which allows unprecedented marbling control within a consolidated structure
Sept. 7, 2022, REHOVOT, Israel — Steakholder Foods Ltd. ( Nasdaq: STKH), (formerly MeaTech 3D: $MITC) an international deep-tech food company at the forefront of the cultured meat industry, is pleased to introduce Omakase Beef Morsels, a revolutionary, richly marbled structured meat product developed using a unique 3D-printing process. Inspired by the marbling standard of Wagyu beef, Omakase Beef Morsels are an innovative culinary achievement elegantly designed as a meat lover’s delicacy for premium dining experiences.
GMP cell CDMO I Peace, Inc. succeeded in converting human dermal fibroblasts into oligodendrocyte precursor cells by direct reprogramming in joint research with Stanford University and the University of California (UCSF)
September 15, 2022, Palo Alto, California – Koji Tanabe of I Peace, Inc. and a researcher Hiroko Nobuta of the University of California, San Francisco (currently assistant professor at Rutgers University) successfully achieved the direct reprogramming: the direct and rapid transformation of Dermal fibroblasts into Oligodendrocyte precursor cells by inducing four genes into the cells. This research was jointly conducted with Prof. Wernig at Sanford University and Prof. Rowitch at UCSF. The research was published in the online edition of an academic journal “Development” on June 24th. [Read more…]
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 118
- Next Page »